Brensocatib

Brensocatib
Clinical data
Trade namesBrinsupri
Other namesAZD7986; INS1007
AHFS/Drugs.comBrinsupri
License data
Routes of
administration		By mouth
Drug classDipeptidyl peptidase 1 inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H24N4O4
Molar mass420.469 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
  • InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
  • Key:AEXFXNFMSAAELR-RXVVDRJESA-N

Brensocatib, sold under the brand name Brinsupri, is a medication used for the treatment of bronchiectasis.[1] It is a dipeptidyl peptidase 1 inhibitor.[1][2] It is taken by mouth.[1]

Brensocatib was approved for medical use in the United States in August 2025.[1][3]

Medical uses

Brensocatib is indicated for the treatment of non-cystic fibrosis bronchiectasis in people aged twelve years of age and older.[1]

History

A phase III clinical trial, known as the ASPEN trial, was conducted to evaluate the safety and efficacy of brensocatib in patients with non-cystic fibrosis bronchiectasis.[4]

Society and culture

Brensocatib was approved for medical use in the United States in August 2025.[5]

Names

Brensocatib is the international nonproprietary name.[6]

Brensocatib is sold under the brand name Brinsupri.[1]

References

  1. ^ a b c d e f g https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217673s000lbl.pdf
  2. ^ Chalmers JD, Usansky H, Rubino CM, Teper A, Fernandez C, Zou J, et al. (October 2022). "Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis". Clinical Pharmacokinetics. 61 (10): 1457–1469. doi:10.1007/s40262-022-01147-w. PMC 9553789. PMID 35976570.
  3. ^ "Novel Drug Approvals for 2025". U.S. Food and Drug Administration (FDA). 15 August 2025. Retrieved 17 August 2025.
  4. ^ Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, et al. (April 2025). "Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis". The New England Journal of Medicine. 392 (16): 1569–1581. doi:10.1056/NEJMoa2411664. PMID 40267423.
  5. ^ "FDA Approves Brinsupri (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease" (Press release). Insmed. 12 August 2025. Retrieved 17 August 2025 – via PR Newswire.
  6. ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
  • Clinical trial number NCT04594369 for "A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)" at ClinicalTrials.gov
  • Clinical trial number NCT03218917 for "Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.